London’s King’s College Hospital (KCH), along with Guy’s and St Thomas’ hospitals, are currently enrolling adult patients for ongoing clinical studies evaluating multiple investigational therapies that may target the inability to produce insulin in people with Type 1 diabetes.
The therapies are ‘investigational’ meaning that they are not approved for use by any regulatory agencies. The aim of these studies is to evaluate if these therapies could improve blood glucose control and reduce the need to take insulin in individuals with Type 1 diabetes. The therapy is delivered by an infusion into the liver and requires the use of immunosuppressive medications to protect the islet cells from the immune system.
The FORWARD Study is therefore recruiting individuals with Type 1 diabetes and who have experienced severe hypoglycaemic events. They must also meet the following key criteria:
- Be between the ages of 18 and 65 (inclusive)
- Have had T1D for at least five years
- Experienced at least two episodes of severe hypoglycaemia in the past year
- Be willing to use continuous glucose monitoring for the duration of the study
Patients will not qualify for the FORWARD Study if they have had prior islet cell therapy, organ transplant, or cell therapy; or advanced complications associated with diabetes.
To find out more, CLICK HERE.
